


[EBMT](#)

[Annual report](#)

[2024](#)



[ScienceEducationPatient Care & Advocacy](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2024](#)[Organisational Structure 2024](#)[Financial Highlights 2024](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Donal McLornan
CMWP Chair
United Kingdom

Major achievements

It is a pleasure to look back on the last 12 months!

We have really refined our study portfolio to enhance scientific output and prioritise contemporary studies. The CMWP has published extensively in this 12-month period, including 22 publications as detailed below, and also presented oral and poster

abstracts at both EBMT24 and ASH24. I would particularly like to highlight the practice harmonisation papers led by the CMWP including Optimisation of allo-HCT in Advanced Mastocytosis. 'Watch this space' for our upcoming international guidelines on clinical-genomic profiling to guide allo-HCT in MDS and the role of allo-HCT in non-classical MPNs and MDS/MPN overlap syndromes! These much needed guidelines will be published imminently.

The CMWP held really productive Business and Educational meetings in Glasgow (AGM) and more recently in Warsaw, November 2024, where we focused on optimizing outcomes in allogeneic HCT for MDS, MPN, and MDS/MPN overlap syndromes. The state-of-the art educational program covered advancements in transplant strategies, covering utilisation of molecular risk stratification in MDS and Myelofibrosis to guide the transplant decision, including how best to address the challenges of managing TP53-mutant MDS, the use of novel agents peri-HCT, and the potential use of CAR-T in MF as developed by Dr. Alexandros Rampotas, University College London, to name a few of the many topics covered. The meeting emphasized a need for more international collaboration and trials focused on these disorders. Future CMWP educational meetings are planned for Rome in September 2025 alongside the ADWP and we hope to see you there for an exciting and innovative event!

Finally, let me express my thanks and admiration for the entire CMWP team, including all the principal investigators, subcommittees and the data management/programming team/ statisticians and members who have worked tirelessly on all of our studies. Their outstanding knowledge, support and collaborative nature has been amazing!



Principal research studies

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Study type

Retrospective Studies

Diseases

Myelodysplastic (MDS) or MDS/MPN

Group

Chronic Malignancies Working Party (CMWP)

Type of treatment

Allogeneic

Principal investigator

Xavier Poiré

Allo-HCT in CLL after multiple pathway inhibitors.

Study type

Retrospective Studies

Diseases

Chronic Lymphocytic Leukaemia (CLL)

Group

Chronic Malignancies Working Party (CMWP)

Type of treatment

Allogeneic

Principal investigator

Michel van Gelder/Olivier Tournilhac

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres.

Study type

Retrospective Studies

Diseases

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Group

Chronic Malignancies Working Party (CMWP)

Type of treatment

Autologous

[Principal investigator](#)

[Patrick Hayden](#)

Key publications

[2024](#)

[Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Donal P McLornan](#)

[Journal](#)

[Leukemia.](#)

[2024](#)

[Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Laurent Garderet](#)

[Journal](#)

[Haematologica.](#)

[2024](#)

[Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Christof Scheid](#)

[Journal](#)

[Blood.](#)

[2024](#)

[Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Yves Chalandon](#)

[Journal](#)

[Blood Adv.](#)

[2024](#)

[Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Thomas Luft](#)

[Journal](#)


[Am J Hematol.](#)

[See the full list of the CMWP 2024 publications](#)




Indicators

Impact factor
(Chronic Malignancies)



2022 2023 2024

Oral presentations	9	9	3
Poster presentations	8	9	8
Educational events	2	2	2



[Event](#)

Chronic Malignancies Working Party Educational Meeting 2024



Event

9th International Transplant and Cellular Therapy Course

Sep 06, 2024 - Sep 08, 2024 / Barcelona, Spain

[Discover more](#)



[Event](#)

[50th Annual Meeting of the EBMT](#)

[Apr 14, 2024 - Jun 17, 2024 / Glasgow, United Kingdom](#)

[Discover more](#)

[VISIT THE CMWP WEBPAGE](#)